Vaxcyte, Inc. — Director's Dealing 2024

Oct 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-10-01

Reporting Person: Eydelman Mikhail (SVP, GEN COUNSEL & CORP SEC)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-01	Common Stock	M	5500	$21.41	Acquired	34123	Direct
2024-10-01	Common Stock	S	1414	$113.381	Disposed	32709	Direct
2024-10-01	Common Stock	S	3056	$114.369	Disposed	29653	Direct
2024-10-01	Common Stock	S	1030	$115.012	Disposed	28623	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-01	Stock Option (right to buy)	$21.41	M	5500	Disposed	2032-05-08	Common Stock (5500)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.795 to $113.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.83 to $114.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.95 to $115.16. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.